CHE Q2 2026 Earnings Call Summary | Stock Taper
Logo
CHE

CHE — Chemed Corporation

NYSE


Q2 2026 Earnings Call Summary

July 29, 2026

Chemed Corporation (CHE) Q2 2026 Earnings Call Summary

1. Key Financial Results and Metrics

  • Total Revenue: Increased by 8.8% year-over-year.
  • Adjusted Diluted EPS: Rose by 41.9% compared to Q2 2025.
  • Cash Flow from Operations: Exceeded $173 million in the quarter.
  • VITAS Revenue: Reached $443.3 million, an 11.9% increase year-over-year.
  • Roto-Rooter Revenue: Commercial revenue grew by 6.8% to $56.8 million; residential revenue increased by 1.7% to $159 million.
  • Adjusted EBITDA: VITAS reported $80.6 million (20.6% increase), while Roto-Rooter’s adjusted EBITDA was $48.5 million, essentially flat year-over-year.

2. Strategic Updates and Business Highlights

  • VITAS Performance: Achieved a 9% increase in admissions, with a strong focus on maintaining a balance between hospital-based and other preadmission locations. The average daily census reached 23,687 patients, marking a significant milestone.
  • Roto-Rooter Developments: Continued focus on commercial sales and water restoration, with a notable acquisition of franchises in South Texas for $12 million. The centralization of billing functions has improved collections and reduced employee count.
  • Franchise Acquisitions: Chemed has repurchased four franchises totaling $33.5 million and plans to pursue additional acquisitions.

3. Forward Guidance and Outlook

  • VITAS Full-Year Guidance:
    • ADC growth revised to 5.75% - 6.25% (previously 4.5% - 5.5%).
    • Revenue growth (excluding Medicare cap impact) updated to 8.25% - 9.25% (previously 6.5% - 7.5%).
    • EBITDA margin (excluding Medicare cap) anticipated at 19.0% - 19.5%.
    • Medicare cap billing limitation reduced to $7 million from $9.5 million.
  • Roto-Rooter Guidance: Remains unchanged with expected revenue growth of 3% - 3.5% and an adjusted EBITDA margin of 21.5% - 22.5%.

4. Bad News, Challenges, or Points of Concern

  • Roto-Rooter Marketing Costs: Increased marketing expenses, particularly for paid leads, impacted profitability. Free leads declined by 13.1%, leading to a heavier reliance on paid leads (59% of total leads).
  • Water Restoration Revenue: Experienced a 6.7% decline due to transitional disruptions in billing and collections.
  • Competitive Pressures: Challenges in lead generation and the evolving digital marketing landscape, particularly with Google, pose ongoing risks to customer acquisition costs.

5. Notable Q&A Insights

  • Sustainability of VITAS Growth: Management expressed confidence in VITAS's ability to maintain growth rates, citing effective strategies and resource management.
  • Roto-Rooter’s Margin Stability: Despite increased marketing costs, management believes the business can sustain margins due to ancillary services and improved collections.
  • Acquisition Strategy: Chemed is actively seeking franchise acquisitions for Roto-Rooter, with expectations of completing a significant acquisition by year-end.
  • Regulatory Environment: Concerns regarding potential changes in Medicare reimbursement rates were addressed, with management indicating no immediate changes are anticipated, though increased oversight is expected.

Overall, Chemed Corporation reported a strong quarter with significant growth in VITAS and stable performance in Roto-Rooter, while navigating challenges in marketing costs and competitive pressures. The outlook remains positive with revised guidance reflecting confidence in continued growth.